

Monoclonal antibody for the detection of *P.vivax*

Salient features of the technology:

- ❖ Technology relates to Hybridoma cell line producing antibody probe against *Plasmodium vivax*.
- ❖ This monoclonal antibody is specific for detection of *P. vivax* non-secretory erythrocytic stage antigen in patient's blood and it is based on immunodiagnostic antibody probe.
- ❖ It has high specificity towards non-secretary antigens of *P. vivax*.
- ❖ The monoclonal antibody has been validated.
- ❖ The technology has been developed up to laboratory scale.
- ❖ It has been developed by National Institute for Malaria Research, New Delhi (an ICMR Institute).
- ❖ An Indian Patent has been granted and patent number is 286941.
- ❖ ICMR is seeking potential agencies for the up-scaling of technology.

=====*******=====